JP2005529904A - 自己免疫疾患の治療のための（３−（２−エチルフェニル）−５−メトキシフェニル）−１ｈ−［１，２，４］−トリアゾールの使用 - Google Patents

自己免疫疾患の治療のための（３−（２−エチルフェニル）−５−メトキシフェニル）−１ｈ−［１，２，４］−トリアゾールの使用 Download PDF

Info

Publication number
JP2005529904A
JP2005529904A JP2004500865A JP2004500865A JP2005529904A JP 2005529904 A JP2005529904 A JP 2005529904A JP 2004500865 A JP2004500865 A JP 2004500865A JP 2004500865 A JP2004500865 A JP 2004500865A JP 2005529904 A JP2005529904 A JP 2005529904A
Authority
JP
Japan
Prior art keywords
cells
triazole
ethylphenyl
methoxyphenyl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004500865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529904A5 (https=
Inventor
ルカ・バッティスティーニ
ジョヴァンナ・ボルセッリーノ
リタ・デ・サンティス
パオロ・カルミナティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2005529904A publication Critical patent/JP2005529904A/ja
Publication of JP2005529904A5 publication Critical patent/JP2005529904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004500865A 2002-05-03 2003-04-15 自己免疫疾患の治療のための（３−（２−エチルフェニル）−５−メトキシフェニル）−１ｈ−［１，２，４］−トリアゾールの使用 Pending JP2005529904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
PCT/IT2003/000237 WO2003092681A1 (en) 2002-05-03 2003-04-15 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2005529904A true JP2005529904A (ja) 2005-10-06
JP2005529904A5 JP2005529904A5 (https=) 2006-06-08

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500865A Pending JP2005529904A (ja) 2002-05-03 2003-04-15 自己免疫疾患の治療のための（３−（２−エチルフェニル）−５−メトキシフェニル）−１ｈ−［１，２，４］−トリアゾールの使用

Country Status (15)

Country Link
US (2) US6797722B2 (https=)
EP (1) EP1501505B1 (https=)
JP (1) JP2005529904A (https=)
KR (1) KR20040111491A (https=)
AT (1) ATE315935T1 (https=)
AU (1) AU2003224453A1 (https=)
CA (1) CA2483904A1 (https=)
DE (1) DE60303296T2 (https=)
DK (1) DK1501505T3 (https=)
ES (1) ES2257666T3 (https=)
MX (1) MXPA04010785A (https=)
PL (1) PL374252A1 (https=)
PT (1) PT1501505E (https=)
TW (1) TWI284532B (https=)
WO (1) WO2003092681A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPH01275571A (ja) * 1988-03-12 1989-11-06 Boehringer Ingelheim Kg 新規３，４，５―置換４ｈ―１，２，４―トリアゾール類およびそれらの製造および用途
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
JP2002502410A (ja) * 1997-06-05 2002-01-22 ジェアンジェ、リミテッド 上皮組織疾患の局所治療における窒素複素環式芳香族誘導体の使用
JP2003513961A (ja) * 1999-11-09 2003-04-15 ラボラトワール テラメックス シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
ATE298740T1 (de) * 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPH01275571A (ja) * 1988-03-12 1989-11-06 Boehringer Ingelheim Kg 新規３，４，５―置換４ｈ―１，２，４―トリアゾール類およびそれらの製造および用途
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
JP2002502410A (ja) * 1997-06-05 2002-01-22 ジェアンジェ、リミテッド 上皮組織疾患の局所治療における窒素複素環式芳香族誘導体の使用
JP2003513961A (ja) * 1999-11-09 2003-04-15 ラボラトワール テラメックス シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物

Also Published As

Publication number Publication date
DE60303296T2 (de) 2006-08-17
PL374252A1 (en) 2005-10-03
EP1501505B1 (en) 2006-01-18
EP1501505A1 (en) 2005-02-02
CA2483904A1 (en) 2003-11-13
ES2257666T3 (es) 2006-08-01
PT1501505E (pt) 2006-05-31
US20050026980A1 (en) 2005-02-03
MXPA04010785A (es) 2005-03-07
DK1501505T3 (da) 2006-05-22
US6797722B2 (en) 2004-09-28
AU2003224453A1 (en) 2003-11-17
ATE315935T1 (de) 2006-02-15
TW200418464A (en) 2004-10-01
DE60303296D1 (de) 2006-04-06
WO2003092681A1 (en) 2003-11-13
KR20040111491A (ko) 2004-12-31
TWI284532B (en) 2007-08-01
US20030207931A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
Haslett et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
Abbas et al. Functional diversity of helper T lymphocytes
Akdis et al. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases
Wilson et al. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity
Sato et al. CC chemokine receptor (CCR) 2 is required for Langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells: absence of CCR2 shifts the Leishmania major–resistant phenotype to a susceptible state dominated by Th2 cytokines, B cell outgrowth, and sustained neutrophilic inflammation
Hysa et al. Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update
Bansal et al. Experimental autoimmune uveitis and other animal models of uveitis: An update
Luger et al. New perspectives on effector mechanisms in uveitis
Renkl et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype
DosReis Cell-mediated immunity in experimental Trypanosoma cruzi infection
Nugent et al. ITE, a novel endogenous nontoxic Aryl hydrocarbon receptor ligand, efficiently suppresses EAU and T-cell–mediated immunity
Chanaud III et al. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism
Suzuki et al. Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis
Atochina et al. Prevention of psoriasis‐like lesions development in fsn/fsn mice by helminth glycans
Yamada et al. Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in “high risk” eyes
JP2007517808A (ja) Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
Constantinescu et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively
Zhang et al. Copolymer 1 inhibits experimental autoimmune uveoretinitis
Di Rosa et al. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis
Ma et al. BAFF maintains T-cell survival by inducing OPN expression in B cells
EP1501505B1 (en) Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h- 1,2,4 -triazole for the treatment of autoimmune diseases
Tsokos et al. Immune cell signaling in autoimmune diseases
Gonnella et al. Inhibition of experimental autoimmune myocarditis: peripheral deletion of TcR Vβ 8.1, 8.2+ CD4+ T cells in TLR-4 deficient mice
Xu et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Rodríguez-Cerdeira et al. Interleukin-2 and other cytokines in candidiasis: expression, clinical significance, and future therapeutic targets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608